Country Club Bank Grows Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Country Club Bank lifted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 112.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 280,716 shares of the company's stock after buying an additional 148,643 shares during the period. Country Club Bank owned about 0.06% of Elanco Animal Health worth $2,922,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ELAN. Hillsdale Investment Management Inc. increased its stake in Elanco Animal Health by 2.1% in the 4th quarter. Hillsdale Investment Management Inc. now owns 43,300 shares of the company's stock valued at $524,000 after purchasing an additional 900 shares in the last quarter. Resonant Capital Advisors LLC increased its stake in Elanco Animal Health by 5.7% in the 1st quarter. Resonant Capital Advisors LLC now owns 29,414 shares of the company's stock valued at $309,000 after purchasing an additional 1,576 shares in the last quarter. Freedom Investment Management Inc. increased its stake in Elanco Animal Health by 9.1% in the 4th quarter. Freedom Investment Management Inc. now owns 20,746 shares of the company's stock valued at $251,000 after purchasing an additional 1,725 shares in the last quarter. Versant Capital Management Inc increased its stake in Elanco Animal Health by 65.9% in the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after purchasing an additional 1,740 shares in the last quarter. Finally, Mitchell & Pahl Private Wealth LLC increased its stake in Elanco Animal Health by 4.0% in the 1st quarter. Mitchell & Pahl Private Wealth LLC now owns 45,489 shares of the company's stock valued at $478,000 after purchasing an additional 1,761 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Wall Street Zen upgraded Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Stifel Nicolaus increased their target price on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. Finally, William Blair upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $15.33.

Elanco Animal Health Trading Down 1.0%

Shares of ELAN stock traded down $0.14 during mid-day trading on Friday, hitting $14.90. 3,844,041 shares of the company's stock were exchanged, compared to its average volume of 5,061,467. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $15.78. The stock has a 50-day simple moving average of $13.45 and a two-hundred day simple moving average of $11.69. The company has a quick ratio of 1.46, a current ratio of 2.71 and a debt-to-equity ratio of 0.68. The stock has a market cap of $7.40 billion, a price-to-earnings ratio of 20.13, a PEG ratio of 2.94 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, beating analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. The firm had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.17 billion. During the same quarter last year, the firm earned $0.34 earnings per share. The firm's revenue for the quarter was down 1.0% compared to the same quarter last year. Equities analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.